Clinical Trials at UW Cancer Center at ProHealth Care

As of July 2026, 50 paid clinical trials are recruiting at UW Cancer Center at ProHealth Care in Waukesha, Wisconsin. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

50 clinical trials at UW Cancer Center at ProHealth Care

·Clear filters·↓ Download CSV

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

177 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

152 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting

Apply to this trial

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

for Pancreatic Carcinoma

118 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06807437·Phase 3·Recruiting

Apply to this trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

for Advanced Hepatocellular Carcinoma

138 locations incl. Berkeley

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07166406·Phase 3·Recruiting

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

246 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting

Apply to this trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for Astrocytoma, IDH-Mutant, Grade 3

Drug: Vorasidenib

82 locations incl. Duarte

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 12+

Code: NCT07215910·Phase 3·Recruiting

Apply to this trial

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

for Grade 2 Meningioma

198 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT03180268·Phase 3·Recruiting

Apply to this trial

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

86 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06649812·Phase 2·Recruiting

Apply to this trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

Drug: Relatlimab

83 locations incl. Dublin

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06029270·Phase 2·Recruiting

Apply to this trial

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

for Recurrent Multiple Myeloma

42 locations incl. Ames

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06232044·Phase 1, Phase 2·Recruiting

Apply to this trial